NSW Cancer Research Education State-wide Seminar Series April 2023
Factors associated with outcomes of CAR-T cell immunotherapy for B cell malignancies.
Professor Cameron TurtleSydney Cancer Partners, in collaboration with the Maridulu Budyari Gumal (SPHERE) Cancer CAG and the NSW Regional Cancer Research Network, will be hosting the 2023 NSW Cancer Research Education State-wide Seminar Series. These online seminars will be held on the 3rd Tuesday of each month.
Lymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a chimeric antigen receptor (CAR) targeted to CD19 is a novel therapy for patients with relapsed and/or refractory B cell malignancies. In this seminar factors associated with outcomes of CAR-T cell therapy in adult B cell malignancies will be discussed using data from a large phase I/II clinical trial of CD19 CAR-T cell immunotherapy (NCT01865617). The impact of lymphodepletion chemotherapy on CAR-T cell engraftment and immune rejection, mechanisms of failure of CAR-T cell immunotherapy, and ex vivo leukapheresis T cell and manufactured product characteristics associated with outcomes will be presented.
Speaker. Professor Cameron Turtle, CLEARbridge Chair of Cancer Immunotherapy, The University of Sydney
Facilitator. Associate Professor Emily Blyth, Clinical Lead, Immune Effector Cell Service, Blood Transplant and Cell Therapy Program, Westmead Hospital